里昂发表研究报告指,诺华(NVS.US) 首席执行官最新对Lp(a)HORIZON研究的评论,可能将研究失败归因于晚期降低Lp(a)相较于基因的终身Lp(a)暴露,所带来的心血管益处有限,这将对包括石药集团(01093.HK) 在内的内地Lp(a)参与者构成压力。石药集团与阿斯利康(AZN.US) 合作开发口服Lp(a)项目YS2302018,目前正处于第一期临床阶段。该行指,市场亦流传关于...
Source Link里昂发表研究报告指,诺华(NVS.US) 首席执行官最新对Lp(a)HORIZON研究的评论,可能将研究失败归因于晚期降低Lp(a)相较于基因的终身Lp(a)暴露,所带来的心血管益处有限,这将对包括石药集团(01093.HK) 在内的内地Lp(a)参与者构成压力。石药集团与阿斯利康(AZN.US) 合作开发口服Lp(a)项目YS2302018,目前正处于第一期临床阶段。该行指,市场亦流传关于...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.